Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLY-102
- Development stage
- Preclinical
- Lead developer
- Glycan Therapeutics
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
GLY-102 is a synthetic heparin-derived oligosaccharide currently in preclinical development by Glycan Therapeutics. It is designed as an anticoagulant for the prophylaxis of deep vein thrombosis (DVT). The drug exerts its therapeutic effect through the selective inhibition of Factor Xa, a key serine protease in the coagulation cascade that mediates the conversion of prothrombin to thrombin. By utilizing chemoenzymatic synthesis to produce a defined oligosaccharide structure, GLY-102 aims to provide a more predictable pharmacological profile and improved safety compared to traditional, heterogeneous heparin products derived from animal sources.
02
Targets
ATIII (Antithrombin III)F10 (Factor Xa)
Beyond the preview
Go deeper on GLY-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLY-102.